Bio-Thera Solutions Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Bio-Thera Solutions is de winst gegroeid met een gemiddeld jaarlijks percentage van 16.9%, terwijl de Biotechs industrie de winst jaarlijks groeide met 5.9%. De inkomsten zijn gegroeid met een gemiddelde van 34.9% per jaar.

Belangrijke informatie

16.9%

Groei van de winst

21.7%

Groei van de winst per aandeel

Biotechs Groei van de industrie	11.3%
Inkomstengroei	34.9%
Rendement op eigen vermogen	-44.6%
Nettomarge	-45.8%
Volgende winstupdate	25 Nov 2024

Recente prestatie-updates uit het verleden

Recent updates

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Oct 09

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Sep 05

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Jun 06

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Apr 18

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Mar 04

Opbrengsten en kosten

Hoe Bio-Thera Solutions geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

SHSE:688177 Opbrengsten, kosten en inkomsten (CNY Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	825	-378	255	758
30 Jun 24	792	-378	228	751
31 Mar 24	711	-371	211	709
31 Dec 23	705	-395	201	769
30 Sep 23	534	-607	187	804
30 Jun 23	541	-565	189	770
31 Mar 23	536	-513	184	705
31 Dec 22	455	-480	174	616
30 Sep 22	803	-62	191	593
30 Jun 22	737	-90	201	582
31 Mar 22	850	81	210	549
31 Dec 21	837	82	216	543
30 Sep 21	492	-263	221	539
30 Jun 21	463	-267	209	546
31 Mar 21	223	-513	181	594
31 Dec 20	183	-513	164	563
30 Sep 20	106	-501	115	522
30 Jun 20	49	-551	86	529
31 Mar 20	20	-600	71	567
31 Dec 19	1	-1,023	401	637
30 Sep 19	1	-1,075	408	1,053
31 Dec 18	0	-553	26	542
31 Dec 17	2	-236	12	237
31 Dec 16	3	-137	11	132

Kwaliteitswinsten: 688177 is momenteel verliesgevend.

Groeiende winstmarge: 688177 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 688177 is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 16.9% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 688177 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 688177 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 0.08% ).

Rendement op eigen vermogen

Hoge ROE: 688177 heeft een negatief Return on Equity ( -44.57% ), omdat het momenteel verliesgevend is.

Bio-Thera Solutions Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Third quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.31 loss in 3Q 2023)

Bio-Thera Solutions, Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.27 loss in 2Q 2023)

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Recent updates

New minor risk - Profitability

Third quarter 2024 earnings released: CN¥0.31 loss per share (vs CN¥0.31 loss in 3Q 2023)

Optimistic Investors Push Bio-Thera Solutions, Ltd. (SHSE:688177) Shares Up 44% But Growth Is Lacking

Bio-Thera Solutions, Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Time To Worry? Analysts Just Downgraded Their Bio-Thera Solutions, Ltd. (SHSE:688177) Outlook

Second quarter 2024 earnings released: CN¥0.28 loss per share (vs CN¥0.27 loss in 2Q 2023)

European Medicines Agency (EMA) Approves Bio-Thera Solutions' BAT1706 (Avzivi, bevacizumab), A Biosimilar Referencing Avastin

Bio-Thera Solutions Initiates Integrated Phase I / Phase III Clinical Trial for BAT3306, A Proposed Biosimilar of Keytruda (Pembrolizumab)

Bio-Thera Solutions Announces Regulatory Filing Acceptance for BAT2206, A Proposed Biosimilar to Stelara in the US and EU

Bio-Thera Solutions, Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Bio-Thera Solutions, Ltd. (SHSE:688177) Shares May Have Slumped 30% But Getting In Cheap Is Still Unlikely

Bio-Thera Solutions Receives Positive CHMP Opinion for Avzivi (Bevacizumab), A Biosimilar Referencing Avastin

Price target decreased by 22% to CN¥42.10

First quarter 2024 earnings released: CN¥0.29 loss per share (vs CN¥0.34 loss in 1Q 2023)

Some Confidence Is Lacking In Bio-Thera Solutions, Ltd. (SHSE:688177) As Shares Slide 27%

Bio-Thera Solutions, Ltd., Annual General Meeting, Apr 18, 2024

Full year 2023 earnings released: CN¥0.95 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Receives IND Clearance From US FDA to Initiate a Phase II Study for BAT8006

Subdued Growth No Barrier To Bio-Thera Solutions, Ltd. (SHSE:688177) With Shares Advancing 30%

Full year 2023 earnings released: CN¥0.97 loss per share (vs CN¥1.16 loss in FY 2022)

Bio-Thera Solutions Announces Initiation of Phase IB / IIA Clinical Trial for BAT6026

FDA Approves Bio-Thera Solutions' Avzivi (Bevacizumab-Tnjn), A Biosimilar Referencing Avastin

Bio-Thera Solutions Announces Positive Results from Phase 3 Study of BAT2206, a Proposed Biosimilar Referencing Stelara

Third quarter 2023 earnings released: CN¥0.31 loss per share (vs CN¥0.21 loss in 3Q 2022)

Chugai Pharmaceutical Co., Ltd., Roche, Genentech, Biogen MA Inc. and Bio-Thera Solutions, Ltd. Withdraw Lawsuit

FDA Approves Bio-Thera Solutions, Ltd.'s Partner Biogen Receives Notification from the United States Food and Drug Administration

Second quarter 2023 earnings released: CN¥0.27 loss per share (vs CN¥0.14 loss in 2Q 2022)

Bio-Thera Solutions, Ltd. Announces Positive Phase 1 Clinical Data for Bat8006 (Folate-Receptor-A-Adc) and Presents Phase 1 Dose Escalation Study At the Bethune Obstetrics and Gynecology Forum

Chugai Files Patent Infringement Lawsuit Against Biogen MA Inc. and Bio-Thera Solutions, Ltd. in the U.S

First quarter 2023 earnings released: CN¥0.34 loss per share (vs CN¥0.27 loss in 1Q 2022)

China NMPA Approves Bio-Thera Solutions' BAT1806, A Biosimilar to Actemra(R) (Tocilizumab)

Bio-Thera Solutions Initiates Phase III Clinical Trial for BAT2306

Third quarter 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.28 loss in 3Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for BAT2606, a Proposed Biosimilar of Nucala (mepolizumab)

Second quarter 2022 earnings released: CN¥0.14 loss per share (vs CN¥0.27 profit in 2Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study for Bat8009, an Antibody Drug Conjugate Targeting B7-H3 (Cd276) for the Treatment of Advanced Solid Tumors

Bio-Thera Solutions, Ltd Announces First Patient Dosed in Phase 1 Study for Bat8006, an Antibody Drug Conjugate Targeting Folate Receptor A for the Treatment of Advanced Solid Tumors

Biogen Inc. and Bio-Thera Solutions, Ltd. Present Positive Phase 3 Data for Tocilizumab Biosimilar Candidate At the Annual European Congress of Rheumatology (EULAR 2022)

Bio-Thera Solutions Announces First Patient Dosed in Australia for BAT7104, a Bispecific Antibody Targeting PD-L1 and CD47 for the Treatment of Advanced Solid Tumors

First quarter 2022 earnings released: CN¥0.27 loss per share (vs CN¥0.26 loss in 1Q 2021)

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Phase 1 Study in Australia Evaluating BAT6026, Anti-OX40 Antibody with Enhanced ADCC Effect, in Combination with BAT1308, Anti-PD-1 Antibody

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Bio-Thera Solutions, Ltd. Announces First Patient Dosed in Australia for BAT6021, ADCC-Enhanced Monoclonal Antibody Targeting TIGIT for Treatment of Solid Tumors

Bio-Thera Solutions Announces Initiation of Phase I Clinical Trials for BAT6005, a Monoclonal Antibody Targeting TIGIT

Third quarter 2021 earnings released

Second quarter 2021 earnings released: EPS CN¥1.08 (vs CN¥0.34 loss in 2Q 2020)

Bio-Thera Solutions Announces First Patient Dosed in Phase III Clinical Trial for BAT2206

Bio-Thera Solutions Initiates Phase Iii Clinical Trial for Bat2506, A Proposed Biosimilar of Simponi® (Golimumab)

Biogen and Bio-Thera Announces Positive Results From Phase 3 Study of BAT1806

First quarter 2021 earnings released: CN¥0.26 loss per share (vs CN¥0.28 loss in 1Q 2020)

New 90-day low: CN¥25.00

Full year 2020 earnings released: CN¥1.27 loss per share (vs CN¥2.96 loss in FY 2019)

New 90-day low: CN¥25.03

Bio-Thera Solutions,Ltd. Announces FDA Accepts Biologics License Application for BAT1706, a Proposed Biosimilar to Avastin®

Bio-Thera Solutions, Ltd. Announces Initiation of Phase I Clinical Trial for BAT1308, a Monoclonal Antibody Targeting PD-1

Bio-Thera Solutions,Ltd. to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: CN¥29.33

Bio-Thera Solutions Announces Licensing Agreement with Biomm S.A. to Distribute and Market BAT1706 in Brazil

New 90-day low: CN¥34.21

Bio-Thera Solutions,Ltd. Submits Marketing Authorization Application (MAA) for BAT1706, a Proposed Biosimilar to Avastin®, to European Medicines Agency (EMA)

New 90-day low: CN¥38.59

Bio-Thera Solutions,Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥43.33

New 90-day low: CN¥43.73

New 90-day low - CN¥47.10

New 90-day low - CN¥47.90

Bio-Thera Solutions, Ltd. to Report First Half, 2020 Results on Aug 28, 2020

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis